Institution of Multiple Daily Insulin Regimen Compared with Twice Daily Pre-Mixed Insulin Regimen for Children with Type 1 Diabetes Mellitus

Christopher Murphy¹ and Sze May Ng^1,

¹Department of Paediatrics, Southport and Ormskirk NHS Trust, United Kingdom

Cite this paper

Christopher Murphy and Sze May Ng. Institution of Multiple Daily Insulin Regimen Compared with Twice Daily Pre-Mixed Insulin Regimen for Children with Type 1 Diabetes Mellitus. American Journal of Clinical Medicine Research. 2013; 1(1):3-5. doi: 10.12691/AJCMR-1-1-2

Abstract

Children and young adults with type 1 diabetes mellitus are usually commenced on either a multiple daily insulin (MDI) regimen or twice daily pre-mixed insulin regimen at diagnosis. The MDI regimen is thought to more closely mimic the normal secretory patterns of endogenous insulin production to improve glycaemic control compared to twice daily or thrice-daily insulin regimens. This study aims to look at the effect on glycaemic control and growth over an 18-month period in children with type 1 diabetes mellitus on a twice-daily pre-mixed bis die (BD) insulin therapy compared to MDI regimen. This is a retrospective study comparing glycaemic control (HbA1c) and growth parameters (height SDS, weight SDS and BMI SDS) at intervals over an 18-month period between children with type 1 diabetes mellitus started on a twice-daily pre-mixed insulin regimen compared to those children started on MDI regimen. No significant difference was found between the two groups. Multiple regression analysis examining independent variables (age at diagnosis, insulin regimen, gender) affecting HbA1c values at 3, 6, 12 and 18 months confirmed that there were no independent factors affecting glycaemic control at any time point A twice-daily insulin regimen and an MDI insulin regimen were equivocal in efficacy of HBA1c control and measures of growth parameters within an 18-month period in paediatric diabetic patients with type 1 diabetes mellitus. Future prospective studies are warranted to address the issues described.

Keywords

Insulin, diabetes, paediatric

Copyright

This work is licensed under a Creative Commons Attribution 4.0 International License. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/

References

[1]	Dixon B, Peter Chase H, Burdick J, et al. Use of insulin glargine in children under age 6 with type 1 diabetes. Pediatr Diabetes 2005; 6(3):150-154.
[2]	Hershon KS, Blevins TC, Mayo CA, Rosskamp R. Once-daily insulin glargine compared with twice daily NPH insulin in patients with type 1 diabetes. Endocr Pract 2004; 10(1):10-17.
[3]	Home PD, Rosskamp R, Forjanic-Klapproth J, Dressler A. A randomized multicentre trial of insulin glargine compared with NPH insulin in people with type 1 diabetes. Diabetes Metab Res Rev 2005; 21(6):545-553.
[4]	Raskin P, Klaff L, Bergenstal R, Halle JP, Donley D, T. A 16-week comparison of the novel insulin analogue insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000; 23(11):1666-1671.
[5]	Rosenstock J, Park G, Zimmerman J. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000; 23(8):1137-1142.
[6]	Schober E, Schoenle E, Van Dyk J, Wernicke-Panten K. Comparative trial between insulin glargine and NPH insulin in children and adolescents with type 1 diabetes mellitus. J Pediatr Endocrinol Metab 2002; 15(4):369-376.
[7]	Wang F, Carabino JM, Vergara CM. Insulin glargine: a systematic review of a long-acting insulin analogue. Clin Ther 2003; 256:1541-1577.
[8]	Hassan, K.; Rodriguez, LM.; Johnson, SE.; Tadlock, S.; Heptulla, RA. A randomized, controlled trial comparing twice-a-day insulin glargine mixed with rapid-acting insulin analogues versus standard neutral protamine Hagedorn (NPH) therapy in newly diagnosed type 1 diabetes. Pediatrics. 2008.
[9]	Päivärinta M, Tapanainen P, Veijola R. Basal insulin switch from NPH to glargine in children and adolescents with type 1 diabetes. Pediatr Diabetes 2008; 9(3):83-90.
[10]	Adhikari S et al. Institution of Basal-Bolus Therapy at Diagnosis for Children With Type 1 Diabetes Mellitus. Pediatrics. 2009 April; 123(4): 673-678.
[11]	Wagner JA. Response shift and glycemic control in children with diabetes. Health Qual Life Outcomes. 2005; 3(1):38.
[12]	Cole T. Growth monitoring with the British 1990 growth reference. Arch Dis Child 1997; 76:47-49.